Carboplatin

Generic Name: Carboplatin

Brand Names: Paraplatin

Drug Type: Small Molecule

Chemical Formula: C_₆H_₁₂N_₂O_₄Pt

CAS Number: 41575-94-4

Unique Ingredient Identifier: BG3F62OND5

Background: Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.

Carboplatin was granted FDA approval on 3 March 1989.

Indication: Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.

Associated Conditions: Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma

Associated Therapies: Conditioning regimens for allogeneic stem cell transplantation therapy

Clinical Trials

Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advance Solid Tumors

Interventions: Drug: Iniparib (SAR240550 - BSI-201)
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2010-10-04

Last Posted Date: 2013-05-24

Lead Sponsor: Sanofi

Target Recruit Count: 18

Registration Number: NCT01213381

Locations: 🇯🇵
Sanofi-Aventis Investigational Site Number 392001, Kobe-Shi, Japan
🇯🇵
Sanofi-Aventis Investigational Site Number 392002, Matsuyama-Shi, Japan

Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy

Not Applicable

Completed

Conditions: Lung Cancer
Hypermethylation
Non Small Cell Lung Carcinoma

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Vidaza
Procedure: Tumor Specimen for Methylation Analysis
Procedure: Blood Sample for Methylation Analysis
Drug: Vinorelbine
Drug: Docetaxel
Drug: Pemetrexed

First Posted Date: 2010-09-27

Last Posted Date: 2015-02-24

Lead Sponsor: University of Miami

Target Recruit Count: 6

Registration Number: NCT01209520

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer

Phase 2

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Abraxane
Drug: Carboplatin

First Posted Date: 2010-09-22

Last Posted Date: 2014-12-15

Lead Sponsor: Duke University

Target Recruit Count: 10

Registration Number: NCT01207102

Locations: 🇨🇳
Peking University School of Oncology/Beijing Cancer Hospital, Beijing, China
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

A Study of Bevacizumab in Combination With Gemcitabine and Carboplatin in Participants With Triple Negative Metastatic Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Bevacizumab
Drug: Carboplatin
Drug: Gemcitabine

First Posted Date: 2010-09-14

Last Posted Date: 2016-05-27

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT01201265

Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma

Phase 2

Terminated

Conditions: Melanoma

Interventions: Drug: Genasense
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2010-09-13

Last Posted Date: 2016-02-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 7

Registration Number: NCT01200342

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: CS-7017
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2010-09-10

Last Posted Date: 2020-07-07

Lead Sponsor: Daiichi Sankyo Co., Ltd.

Target Recruit Count: 16

Registration Number: NCT01199055

Locations: 🇰🇷
Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

Phase 2

Completed

Conditions: Ovarian Clear Cell Cystadenocarcinoma
Stage III Ovarian Cancer
Stage IV Ovarian Cancer

Interventions: Drug: Carboplatin
Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Temsirolimus

First Posted Date: 2010-09-08

Last Posted Date: 2019-08-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 90

Registration Number: NCT01196429

Locations: 🇺🇸
Cadence Cancer Center in Warrenville, Warrenville, Illinois, United States
🇺🇸
Lahey Hospital and Medical Center, Burlington, Massachusetts, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 142 locations

Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer

Phase 3

Completed

Conditions: Esophageal Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Stage IIA Esophageal Cancer AJCC v7
Stage IIB Esophageal Cancer AJCC v7
Stage IIIA Esophageal Cancer AJCC v7
Stage IB Esophageal Cancer AJCC v7
Stage IIIB Esophageal Cancer AJCC v7

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Quality-of-Life Assessment
Radiation: Radiation Therapy
Procedure: Therapeutic Conventional Surgery
Biological: Trastuzumab

First Posted Date: 2010-09-08

Last Posted Date: 2023-09-07

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 203

Registration Number: NCT01196390

Locations: 🇺🇸
University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸
Weiss Memorial Hospital, Chicago, Illinois, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

and more 628 locations

Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

Phase 2

Completed

Conditions: Bladder Cancer
Transitional Cell Cancer of the Renal Pelvis and Ureter
Ureter Cancer
Urethral Cancer

Interventions: Drug: carboplatin
Drug: gemcitabine hydrochloride
Drug: Placebo
Drug: vandetanib

First Posted Date: 2010-08-31

Last Posted Date: 2019-05-16

Lead Sponsor: Cardiff University

Target Recruit Count: 82

Registration Number: NCT01191892

Locations: 🇬🇧
Beatson West of Scotland Cancer Centre, Glasgow, Scotland, United Kingdom
🇬🇧
Royal Bournemouth General Hospital, Bournemouth, United Kingdom
🇬🇧
Royal Surrey County Hospital, Surrey, United Kingdom

and more 18 locations

Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: Trametinib (GSK1120212)
Drug: Docetaxel
Drug: nab-Paclitaxel
Drug: Pemetrexed
Drug: Erlotinib
Drug: Carboplatin
Drug: Cisplatin

First Posted Date: 2010-08-31

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 169

Registration Number: NCT01192165

Locations: 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy